Spruce Biosciences. has filed a patent for a pharmaceutical composition to treat Congenital adrenal hyperplasia (CAH). The method involves administering a CRF1 receptor antagonist along with reduced doses of glucocorticoids to lower hormone levels in patients. GlobalData’s report on Spruce Biosciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Spruce Biosciences Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Spruce Biosciences, Peptide pharmacophores was a key innovation area identified from patents. Spruce Biosciences's grant share as of January 2024 was 16%. Grant share is based on the ratio of number of grants to total number of patents.

Treatment of congenital adrenal hyperplasia using crf1 receptor antagonist

Source: United States Patent and Trademark Office (USPTO). Credit: Spruce Biosciences Inc

A patent application (Publication Number: US20230414627A1) discloses a method for treating congenital adrenal hyperplasia (CAH) in humans. The method involves administering a CRF1 receptor antagonist or a pharmaceutically acceptable salt, along with a reduced second dose of a glucocorticoid compared to the first dose. The treatment aims to reduce levels of androstenedione (A4), adrenocorticotropic hormone (ACTH), or 17-hydroxyprogesterone (17-OHP) in the subject from baseline levels.

The method includes reducing A4, ACTH, or 17-OHP levels by at least 5% from baseline, with further reductions of 10%, 15%, 20%, or 25% also being claimed. The treatment not only aims to reduce these hormone levels but also maintain them at reduced levels post 24 hours, 4 weeks, and 6 weeks. The patent application specifies the use of specific glucocorticoids like hydrocortisone and CRF1 receptor antagonists like Compound 1, with dosing regimens and administration methods detailed for optimal efficacy. The method also highlights the importance of timing in administering the CRF1 receptor antagonist and glucocorticoid to achieve the desired therapeutic effects in treating CAH.

To know more about GlobalData’s detailed insights on Spruce Biosciences, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies